Own a part of our business. Capital at Risk.
View our pitch
Mergermarket Interview with Stablepharma CEO on future IPO and Series B raise
Stablepharma closed Series A funding round of $6.4m to progress fridge-free vaccines and mRNA/LNP stabilisation technologies
Johnny Sutton joins the Stablepharma Ltd Board of Directors
Stablepharma sign exclusive supply agreement to produce the world’s first fridge-free Tetanus diphtheria vaccine
New Data demonstrates StablevaX™-Td Vaccine Stable after 12 months at +45°C
Stablepharma and a World Leader in Sterile Manufacturing Announce Partnership to Manufacture the first Fridge-Free Tetanus diphtheria (Td) Vaccine
How British research could hold the key to taming Monkeypox and fridge-free vaccines
Stablepharma’s CEO is amongst 29 of London’s Most Impressive & Successful Directors in the Biotech Space
A new generation of COVID-19 vaccines – the latest developments from preclinical and clinical trials?
Stablepharma Ltd has achieved a scientific breakthrough, demonstrating that a fridge-free Tetanus diphtheria (Td) vaccine is possible
Stablepharma Ltd welcomes another new member to the UK Team
Daniela Maria Briceño Garcia joins the Stablepharma Science Team